ArticleThe Lancet regional health. Western Pacific2026
The toll of tobacco: smoking-attributable health spending in South Korea, 2014-2024. National claims evidence for cost recovery.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: South Korean policymakers are weighing tobacco control and financing options amid rising health-care costs. This study estimates the direct medical expenditure attributable to active and second-hand smoking (SHS) using Korea's National Health Insurance Service (NHIS) claims data (2014-2024) and quantifies the fiscal burden borne by the public insurer vs. households. Methods: Annual NHIS claims data for all beneficiaries for the period 2014-2024 were linked with disease-specific Population Attributable Fractions (PAFs) derived from the Global Burden of Disease (GBD) study. Costs were stratified by sex, age, income group, and payer (NHIS vs. out-of-pocket) and expressed in 2024 US dollars. Findings: Smoking-attributable medical spending totaled USD 29.86 billion over the period from 2014 to 2024. In 2024 alone, costs reached USD 3.38 billion, representing 19.7% of expenditure for the analyzed conditions and approximately 4.0% of national health expenditure. The fiscal burden was shared between the public insurers (82.5%) and households (17.5% out-of-pocket). Costs were highest among men (80.1%) and adults aged 50-79 (80.7%), reflecting a "lagged epidemic" driven by historical exposure. The top 10 conditions accounted for 88.2% of total smoking-attributable spending, with cancers absorbing 35.2% and cardiometabolic diseases absorbing 53.1%. Costs for men were driven by active smoking (∼90%), while costs for women were largely attributable to SHS, which accounted for 48% of their total costs compared to 9% for men. Interpretation: Past smoking choices of South Koreans have left a legacy of current medical costs that many non-smokers are now facing. Women and men who never chose to smoke are succumbing to illness due to SHS which accounts for 16.5% of overall costs. New generations of workers must bear these costs through taxation and premiums to finance South Korea's health care system. The current decline in smoking prevalence is insufficient to arrest the rising financial momentum of historical exposure. These findings provide evidence for a way out of the cycle by correcting prices of tobacco to include the social costs. A polluter-pays framework would recover public health expenditures and deter new generations from imposing consequences of their personal choices on others. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.